Public Law 117-350 | Public Law 117–350: To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.

As enacted: this collection preserves GovInfo's listed Beta USLM public-law XML, including printed amendment instructions and legislative history. Later amendments are not consolidated here; availability in this XML inventory does not establish completeness of all laws enacted by Congress.

?6261

PUBLIC LAW 117–350—JAN. 5, 2023

CHILDHOOD CANCER SURVIVORSHIP, TREATMENT, ACCESS, AND RESEARCH REAUTHORIZATION ACT OF 2022

136 STAT. 6262

Public Law

117–350

117th Congress

An Act

To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.

Jan. 5, 2023

[S. 4120]

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022.

SECTION 1.

42 USC 201 note.

SHORT TITLE.

This Act may be cited as the “

Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022

” or the “

Childhood Cancer STAR Reauthorization Act

”.

SEC. 2.

REAUTHORIZING AND IMPROVING THE CHILDHOOD STAR ACT.

(a)

Children’s Cancer Biorepositories.—

Section 417E of the Public Health Service Act (42 U.S.C. 285a–11)

is amended

—

(1)

in subsection (a)—

(A)

in paragraph (2)(A), by

inserting

before the period at the end of the second sentence the following: “, such as collected samples of both solid tumor cancer and paired samples”;

(B)

in paragraph (9), by

striking

“Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018” and

inserting

“Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022”;

(C)

redesignating

paragraph (10) as paragraph (11); and

(D)

inserting

after paragraph (9) the following:

“(10)

Report on researcher access to children’s cancer biorepository samples.—

Not later than 2 years after the date of enactment of the Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022, the Director of NIH shall—

“(A)

Review.

conduct a review of the procedures established under paragraph (2)(C) and other policies or procedures related to researcher access to such biospecimens to identify any opportunities to reduce administrative burden, consistent with paragraph (2)(D), in a manner that protects personal privacy to the extent required by applicable Federal and State privacy law, at a minimum; and

“(B)

submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report on the findings of the review under subparagraph (A) and whether the Director of NIH plans to make any changes to the policies or procedures considered in such review, based on such findings.”

; and136 STAT. 6263

(2)

in subsection (d), by

striking

“2019 through 2023” and

inserting

“2024 through 2028”.

(b)

Cancer Survivorship Programs.—

Section 201 of the Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018 (Public Law 115–180)

42 USC 285a–11a note.

is amended

—

(1)

in subsection (a)—

(A)

in the subsection heading, by

striking

“Pilot Programs to Explore” and

inserting

“Research to Evaluate”

(B)

in paragraph (1)—

(i)

striking

“may make awards to eligible entities to establish pilot programs” and

inserting

“shall, as appropriate, make awards to eligible entities to conduct or support research”;

(ii)

striking

“model systems” and

inserting

“approaches”;

(iii)

inserting

“and adolescent” after “childhood”; and

(iv)

striking

“evaluation of models for”;

(C)

in paragraph (2)—

(i)

in subparagraph (A), in the matter preceding clause (i), by

inserting

“within the existing peer review process,” after “practicable,”; and

(ii)

in subparagraph (B)(v), by

striking

“in treating survivors of childhood cancers” and

inserting

“in carrying out the activities described in paragraph (1)”; and

(D)

in paragraph (3)(B)(v), by

striking

“design of systems for the effective transfer of treatment information and care summaries from cancer care providers to other health care providers” and

inserting

“design tools to support the secure electronic transfer of treatment information and care summaries between health care providers or, as applicable and appropriate, longitudinal childhood cancer survivorship cohorts”; and

(2)

in subsection (b)—

(A)

in each of paragraphs (1) and (2), by

striking

“date of enactment of this Act” and

inserting

“date of enactment of the Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022”; and

(B)

in paragraph (1)—

(i)

striking

subparagraphs (A) and (C);

(ii)

redesignating

subparagraph (B) as subparagraph (A); and

(iii)

adding

at the end the following:

“(B)

recommendations for enhancing or promoting activities of the Department of Health and Human Services related to workforce development for health care providers136 STAT. 6264 who provide psychosocial care to pediatric cancer patients and survivors.”

Approved January 5, 2023.

LEGISLATIVE HISTORY—S. 4120:

CONGRESSIONAL RECORD, Vol. 168 (2022):

Dec. 20, considered and passed Senate.

Dec. 22, considered and passed House.

○

Public Law 117–350: To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.

SHORT TITLE.

REAUTHORIZING AND IMPROVING THE CHILDHOOD STAR ACT.

Children’s Cancer Biorepositories.—

Report on researcher access to children’s cancer biorepository samples.—

Cancer Survivorship Programs.—

LEGISLATIVE HISTORY—S. 4120:

CONGRESSIONAL RECORD, Vol. 168 (2022):

Continue your research in ChatGPT or Claude